文献速递骨质疏松与代谢性骨病

罗莫佐单抗不改善桡骨远端体积骨密度但与骨强度早期变化相关

Romosozumab does not improve volumetric bone mineral density at distal radius but is associated with early changes in bone strength: a prospective study.
PubMed 文献 · Osteoporos Int · 2026-06-18

该前瞻性研究纳入49例接受罗莫佐单抗治疗12个月的绝经后骨质疏松女性,采用HR-pQCT及微有限元分析评估桡骨远端。结果示桡骨远端皮质与松质vBMD及微结构无显著增加,但皮质失效载荷与剪切强度早期升高;腰椎、股骨颈及全髋aBMD分别显著增加11.6%、8.3%、3.1%(均p<0.001)。

要点

  • 罗莫佐单抗治疗12个月未显著增加桡骨远端皮质或松质vBMD及微结构参数。
  • 微有限元分析显示皮质失效载荷与剪切强度早期升高,提示骨力学行为可能改善。
  • 腰椎、股骨颈、全髋aBMD分别增加11.6%、8.3%、3.1%(均p<0.001)。

核心结论

  • 罗莫佐单抗治疗与桡骨远端生物力学参数的早期适度变化相关,但该部位vBMD无显著改善。
  • 罗莫佐单抗可能通过骨密度增益之外的途径改善骨骼健康。

研究设计与样本

  • 前瞻性研究,纳入49例接受罗莫佐单抗治疗12个月的绝经后骨质疏松女性。
  • 基线、3、6、12个月行HR-pQCT(含锥形束CT)及微有限元分析,并行腰椎、股骨颈、全髋DXA。
  • HR-pQCT参数轨迹采用混合效应模型分析。

主要发现

  • 桡骨远端皮质或松质vBMD及微结构参数未见显著增加。
  • 微有限元分析显示皮质失效载荷与剪切强度早期增加。
  • 腰椎、股骨颈、全髋aBMD分别显著增加11.6%、8.3%、3.1%(均p<0.001)。

临床怎么用

  • 对接受罗莫佐单抗治疗的骨质疏松患者,桡骨远端常规密度扫描未见vBMD改善时,可考虑HR-pQCT等详细影像评估骨强度变化。
  • 解读罗莫佐单抗疗效时需结合不同骨骼部位,腰椎与髋部aBMD显著增加而桡骨远端vBMD无显著变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We evaluated how romosozumab affects bone structure, density, and strength at the wrist over 12 months. Volumetric bone mineral density did not increase, but high-resolution quantitative computed tomography imaging showed modest improvements in bone strength. These findings suggest that romosozumab may improve bone quality even in areas where density changes are not seen with standard scans and highlight the importance of using more detailed imaging to fully understand how osteoporosis treatments work across different skeletal sites. PURPOSE: Romosozumab (ROMO) is a monoclonal antibody that inhibits sclerostin, promoting bone formation and suppressing resorption. While ROMO leads to substantial BMD gains at the lumbar spine and the hip, its effects on distal radius volumetric BMD (vBMD) remain unclear. High-resolution peripheral quantitative computed tomography (HR-pQCT) allows for detailed assessment of bone microarchitecture and strength at peripheral regions. We aimed to evaluate the effects of 12 months of ROMO on vBMD, microarchitecture and biomechanical properties of the distal radius using HR-pQCT. METHODS: We did a prospective study on 49 postmenopausal women with osteoporosis treated with ROMO for 12 months who underwent HR-pQCT with Cone Beam CT and microfinite element analysis (uFEA) assessments at baseline, 3, 6, and 12 months. We also performed DXA at lumbar spine, femoral neck, and total hip. HR-pQCT parameters trajectories were analyzed using mixed-effects modeling. RESULTS: No significant increases were observed in cortical or trabecular vBMD or microarchitectural parameters at the distal radius. On the other hand, uFEA showed early increases in cortical failure load and shear strength, suggesting potentially improved bone mechanical behavior. Lumbar spine, femoral neck, and total hip aBMD significantly increased by 11.6%, 8.3%, and 3.1%, respectively (all p < 0.001). CONCLUSION: ROMO treatment was associated with modest early changes in biomechanical parameters, without significant improvement in vBMD at the distal radius. ROMO treatment might improve skeletal health beyond BMD gains.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Diz-Lopes M, Rovetta CF, Pollastri F, et al. Romosozumab does not improve volumetric bone mineral density at distal radius but is associated with early changes in bone strength: a prospective study. Osteoporos Int. 2026. PMID: 42313178. doi:10.1007/s00198-026-08113-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。